<DOC>
	<DOCNO>NCT02065856</DOCNO>
	<brief_summary>This trial open , national , multi-centre trial . The trial initiate December 2013 subject receive treatment 6 week . Safety monitoring perform ongoing basis Clinical Safety Group immediate access Adverse Events register clinical database . The composition , procedure deliverables Clinical Safety Group detail Safety Agreement prior trial start .</brief_summary>
	<brief_title>An Open Trial Assess Tolerability AVANZ® Salsola Immunotherapy</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>A clinical history Salsola kali pollen induce allergic rhinoconjunctivitis without asthma least one year prior trial entry . Positive Skin Prick Test Salsola kali pollen ( wheal diameter ≥ 3 mm ) . Documenting last 5 year positive specific Immunoglobulin E Salsola kali pollen ( ≥ Class 2 ; ≥0.70 KU/L ) . Forced expiratory volume one second 1 &lt; 70 % predict value screen adequate pharmacologic treatment . Uncontrolled severe asthma . History severe asthma exacerbation emergency room visit admission asthma previous 12 month . At screen , current symptom , treatment , upper respiratory tract infection , acute sinusitis , acute otitis medium relevant infection ( serous otitis medium exclusion criterion ) . Treatment parenteral corticosteroid , oral corticosteroid antiIgE previous 3 month study ( except steroid need rescue medication ) . Currently treat angiotensin convert enzyme ( ACE ) inhibitor , tricyclic antidepressant , βblockers , mono amine oxidase inhibitor ( MAOIs ) drug contain alum ( e.g . antacid ) take daily basis . Immunotherapy Cupressus arizonica Salsola kali pollen extract within previous 5 year ( initiation subcutaneous immunotherapy acceptable treatment discontinue reach maintenance dose ; SLIT 3 month last 5 year accept ) concomitant immunotherapy allergen . History anaphylactic shock due e.g . food , insect venom , exercise drug . History severe recurrent angioedema .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>